Blondeau JM, Tillotson GS

Language: Spanish
References: 18
Page: 573-582
PDF size: 350.15 Kb.

ABSTRACT

Uncomplicated urinary infections are a significant and growing cause of morbidity amongst young women. Commonly these infections are caused by Escherichia coli or Staphylococcus saprophyticus. Escherichia coli is resistant to several empirical antibiotics: amoxicilin, trimetoprima-sulfametozaxol and, more recently, to some more old flouroquinolons. Gemifloxacin is a flouroquinolon with an excellent in vitro activity against many community acquired bacteria which cause respiratory or urinary infections. This antibiotic has a very unique and dual action mechanism directed against girasa and topoisomerasa II DNA, which grants minimum low inhibitory concentrations against Escherichia coli, Klebsiella and S. saprophyticus species and others attacking respiratory system. Young women with uncomplicated urinary infections were evaluated in two random clinical studies; they were treated with 320 mg gemifloxacin once a day for three days. Gemifloxacin was compared to ofloxacin or ciprofloxacin in approved doses and durations and it proved to be useful with clinical success rates of 95% or more in both studies. Gemifloxacin showed to be safe and well tolerated. A dose a day is a safe and useful alternative amongst current empirical options to treat patients with uncomplicated urinary infections.

REFERENCES

1. Warren JW, Arbutryn E, Hebel JR, Johnson JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Inf Dis 1999;29:745-58.

2. National Institutes of Health. The National Kidney and Urologic Diseases Advisory Board 1990 long-range plan-window on the 21st century. Bethesda: National Institutes of Health, 1990; NIH publication number.90-583.

3. Foxman B, Frerichs RR. Epidemiology of urinary tract infection: I diaphragm use and sexual intercourse. Am J Public Health 1985;75:1308-13.

4. Schappert SM. National Ambulatory Medical Care Survey: 1991 summary. Vital Health Stat 1994;13:1-110.

5. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997;11:551-81.

6. Andrade SS, Sader HS, Jones RN, Pereira AS, et al. Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin-America: time for local guidelines? Mem Inst Oswaldo Cruz 2006;101:741-8.

7. Zhanel GG, Karlowsky JA, Harding GK, et al. A Canadian national surveillance study of urinary tract isolates from outpatients: Blondeau JM y Tillotson GS comparison of the activities of trimethprim-sulphamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. Antimicrob Agents Chemother 2000;44:1089-92.

8. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO. SENS project. J Antimicrob Chemother 2003;51:69-76.

9. Blondeau JM, Hansen G, Metzler KL, Borsos S, et al. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin an advanced fluoroquinolone. Int J Antimicrob Agents 2003;22:147-54.

10. Fuchs PC, Barry AL, Brown SD. In vitro activity of gemifloxacin against contemporary clinical isolates from 11 North American medical centers and assessment of disk diffusion interpretive criteria. Diagn Microbiol Infect Dis 2000;38:243-53.

11. McCloskey L, Moore T, Niconovich N, et al. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. J Antimicrob Chemother 2000;45 (suppl S1):S13-S21.

12. JI oh JI, Paek KS, Ahn MJ. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob Agents Chemother 1996;40:1564-8.

13. Cormican MG, Jones RN. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob Agents Chemother 1997;41:204-11.

14. Wagenlehner FME, Naber KG. Antibiotic treatment for urinary tract infections: pharmacokinetic/phamacodynamic principles. Exp Rev Anti-Inf Ther 2004;2:923-31.

15. Naber CK, Hammer M, Kinzig-Schippers M, et al. Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Antimicrob Agents Chemother 2001;45:3524-30.

16. SB-265805/RSD-101NMG/1 Study 003 report, December 2001. A double-blind, multicentre, parallel group, dose ranging study to compare the efficacy and safety of oral SB 256805 (gemifloxacin) at doses of 160 mg and 320 mg once daily versus oral ofloxacin 200 mg twice daily for 3 days in the treatment of uncomplicated urinary tract infections. Smith-Kline Beecham internal clinical study report.

17. SB-265805/RSD-101NMT/1 Study 053 report. A double-blind, double-dummy, multicenter, parallel group study to compare the efficacy and safety of gemifloxacin given either as a single oral dose of 640mg or as 320mg once daily for three days versus oral ciprofloxacin 250 mg twice a day for three days in the treatment of uncomplicated urinary tract infections in female patients. Smith-Kline Beecham internal clinical study report.

18. Ball P, Mandell L, Patou G, Dankner W, Tillotson G. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004;23:421-9.